RT Journal Article
T1 Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis.
A1 López-Rodríguez, Rosario
A1 Ferreiro-Iglesias, Aida
A1 Lima, Aurea
A1 Bernardes, Miguel
A1 Pawlik, Andrzej
A1 Paradowska-Gorycka, Agnieszka
A1 Świerkot, Jerzy
A1 Slezak, Ryszard
A1 Dolžan, Vita
A1 González-Álvaro, Isidoro
A1 Narváez, Javier
A1 Cáliz, Rafael
A1 Pérez-Pampín, Eva
A1 Mera-Varela, Antonio
A1 Vidal-Bralo, Laura
A1 Acuña Ochoa, José Gorgonio
A1 Conde, Carmen
A1 Gómez-Reino, Juan J
A1 González, Antonio
AB About 70 genetic studies have already addressed the need of biomarkers to predict the response of patients with rheumatoid arthritis (RA) to methotrexate (MTX) treatment. However, no genetic biomarker has yet been sufficiently validated. Here, we aimed to replicate a selection of 25 SNPs in the largest collection of patients up to date, which consisted of 915 patients treated with MTX. The change in disease activity (measured as ΔDAS28) from baseline was considered the primary outcome. In addition, response according to widely used criteria (EULAR) was taken as secondary outcome. We considered consistency between outcomes, P values accounting for the number of SNPs, and independence from potential confounders for interpretation of the results. Only the rs1801394 SNP in MTRR fulfilled the high association standards. Its minor allele was associated with less improvement than the major allele according to ΔDAS28 (p = 0.0016), and EULAR response (p = 0.004), with independence of sex, age, baseline DAS28, smoking, seropositivity, concomitant corticosteroid use or previous treatments. In addition, previous evidence suggests the association of this SNP with response to MTX in another autoimmune disease, juvenile idiopathic arthritis, and with high intracellular folate levels, which could contribute to poor response.
YR 2018
FD 2018-05-09
LK http://hdl.handle.net/10668/12441
UL http://hdl.handle.net/10668/12441
LA en
DS RISalud
RD Apr 12, 2025